- Home
- AUTL vs MLYS Comparison
AUTL vs MLYS Comparison
Compare AUTL & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | MLYS |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.8M | 3.1B |
| IPO Year | 2018 | 2023 |
Fundamental Metrics
Financial Performance| Metric | AUTL | MLYS |
|---|---|---|
| Price | $1.75 | $37.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $8.33 | ★ $47.33 |
| AVG Volume (30 Days) | ★ 3.9M | 1.6M |
| Earning Date | 11-12-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $51,128,000.00 | N/A |
| Revenue This Year | $658.11 | N/A |
| Revenue Next Year | $91.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 406.67 | N/A |
| 52 Week Low | $1.11 | $8.24 |
| 52 Week High | $2.80 | $47.65 |
Technical Indicators
Market Signals| Indicator | AUTL | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 64.58 | 44.79 |
| Support Level | $1.56 | $36.01 |
| Resistance Level | $1.69 | $38.40 |
| Average True Range (ATR) | 0.10 | 1.79 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 86.96 | 37.98 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.